Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Merus N.V. CS (MRUS)

Merus N.V. CS (MRUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 448,263
  • Shares Outstanding, K 23,408
  • Annual Sales, $ 37,140 K
  • Annual Income, $ -28,660 K
  • 60-Month Beta 0.10
  • Price/Sales 13.66
  • Price/Cash Flow N/A
  • Price/Book 5.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.44
  • Number of Estimates 3
  • High Estimate -0.37
  • Low Estimate -0.49
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -29.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.08 +19.09%
on 02/03/20
19.34 -1.01%
on 02/18/20
+2.17 (+12.78%)
since 01/17/20
3-Month
13.03 +46.97%
on 01/02/20
19.34 -1.01%
on 02/18/20
+3.50 (+22.36%)
since 11/18/19
52-Week
11.00 +74.09%
on 02/26/19
20.95 -8.59%
on 09/23/19
+7.79 (+68.57%)
since 02/15/19

Most Recent Stories

More News
ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe's Most Competitive Science Region

IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced...

IPATF : 0.4278 (-2.99%)
IPA.VN : 0.600 (+5.26%)
GMAB : 24.07 (+0.80%)
MRUS : 19.15 (+2.90%)
Merus Announces Chief Executive Officer Transition

-- Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer --

MRUS : 19.15 (+2.90%)
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 14.89% and 15.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

MRUS : 19.15 (+2.90%)
Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage company developing innovative, full-length...

MRUS : 19.15 (+2.90%)
Can European Buyouts Aid Canopy Growth's (CGC) Q2 Earnings?

Canopy Growth (CGC) acquires a number of European companies to expand its production base across a region that promises great opportunities.

MRUS : 19.15 (+2.90%)
EYEN : 4.27 (-1.16%)
PRVL : 16.94 (-2.64%)
CGC : 21.94 (-0.86%)
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q2 Earnings?

A series of acquisitions is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal second quarter.

MRUS : 19.15 (+2.90%)
EYEN : 4.27 (-1.16%)
CGC : 21.94 (-0.86%)
PRVL : 16.94 (-2.64%)
Merus Announces Pricing of Public Offering of Common Shares

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics(R), today announced the...

MRUS : 19.15 (+2.90%)
Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics(R), today announced the launch...

MRUS : 19.15 (+2.90%)
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions

Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets...

MRUS : 19.15 (+2.90%)
Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Company to host investor call on Monday, October 28th at 8:00AM ET

MRUS : 19.15 (+2.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade MRUS with:

Business Summary

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is...

See More

Key Turning Points

2nd Resistance Point 20.05
1st Resistance Point 19.60
Last Price 19.15
1st Support Level 18.44
2nd Support Level 17.74

See More

52-Week High 20.95
Last Price 19.15
Fibonacci 61.8% 17.15
Fibonacci 50% 15.98
Fibonacci 38.2% 14.80
52-Week Low 11.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar